MicroRNA- 103 as a novel potential biomarker of poor prognosis and durg resistance in solid tumours.

BACKGROUD

Multiple studies have reported that microRNA-103 is unregulated in a variety of tumours, involved in tumorigenesis, and associated with tumour prognosis, so a systematic review and meta-analysis were performed to determine the relationship between microRNA-103 and the prognosis of solid tumours.

METHODS

The PubMed, Web of Science, and EMBASE databases were searched to retrieve articles to determine the relationship between microRNA-103 and tumour prognosis. Relevant articles were graded according to the Newcastle-Ottawa Scale (NOS). The 95% confidence interval (CI) was calculated by the fixed-effect/random-effect models and the risk ratio (RR) were summarised.

RESULTS

Eight out of 162 retrieved articles were included in this review, with an average NOS score of 7.2 points. Four studies of tissue samples and four studies of serum samples suggested that the overexpression of microRNA-103 was associated with overall survival (RR = 2.65, 95% CI: 1.79-3.93, P = 0.000 and RR = 3.31, 95% CI: 2.04-5.36, P = 0.000, respectively).

CONCLUSION

This meta-analysis, combining 9 studies, found that overexpression of miRNA-103 is associated with poor prognosis in solid tumours, particularly in serum samples. Sensitivity analysis confirmed that high tissue expression correlates with poor outcomes. miRNA-103's role in tumor progression suggests its potential as a prognostic biomarker for solid tumors, warranting further research for clinical applications.